 {#cpt690-sec-0016}

Study Highlights1**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**☑ The human CYP supergene family harbors a multitude of single nucleotide variants (SNVs) and copy number variations. The frequencies of these pharmacogenetically important polymorphisms have mostly been studied in relatively small populations.**WHAT QUESTION DID THIS STUDY ADDRESS?**☑ This study utilized next‐generation sequencing data from 56,945 unrelated individuals from five major populations to derive representative haplotype frequencies. In total, we report the frequencies of 176 alleles distributed over the 12 *CYP* genes with highest relevance for human drug metabolism and aggregate this dataset into worldwide patterns of predicted functional variability.**WHAT THIS STUDY ADDS TO OUR KNOWLEDGE**☑ Our analyses quantify the large extent of genetic variability between major populations on an unprecedented scale and reveal unexpectedly large interethnic differences. This genetic variability is expected to result in major functional differences, especially for the metabolism of CYP2C19, CYP2D6, and CYP3A substrates.**HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?**☑ This study reveals clinically interethnic differences in human drug metabolism that provide important information for the guidance of personalized drug therapy and the design of clinical trials.

 {#cpt690-sec-0001}

Drug response is highly variable between individuals, resulting in 40--70% of patients exhibiting a lack of efficacy of pharmacological treatment or adverse drug reactions.[1](#cpt690-bib-0001){ref-type="ref"}, [2](#cpt690-bib-0002){ref-type="ref"} Importantly, it is estimated that 15--30% of this variability is caused by genetic polymorphisms.[2](#cpt690-bib-0002){ref-type="ref"} Cytochrome P450 (CYP) enzymes and their roles in drug metabolism have been extensively studied and constitute major determinants of drug response, as they are responsible for 80% of phase 1 drug metabolism and 65--70% of drug clearance.[3](#cpt690-bib-0003){ref-type="ref"}, [4](#cpt690-bib-0004){ref-type="ref"} Furthermore, metabolism by polymorphic phase 1 enzymes, primarily CYPs, has been implicated in an increased risk of drugs to cause adverse drug reactions.[5](#cpt690-bib-0005){ref-type="ref"}

The human *CYP* supergene family consists of 57 genes, however, 12 of the encoded enzymes are responsible for more than 75% of all phase 1 drug oxidation reactions.[4](#cpt690-bib-0004){ref-type="ref"} Importantly, these *CYP* genes are highly polymorphic and harbor a large repertoire of single nucleotide variants (SNVs) and copy number variations. This diversity is primarily based on low evolutionary constraints due to the lack of essential endogenous functions of the encoded gene products and genetic drift. Yet, although the vast majority of such polymorphisms are rare with minor allele frequencies (MAFs) \<1%,[6](#cpt690-bib-0006){ref-type="ref"} pharmacogenetic testing in the clinics is currently restricted to validated and experimentally characterized variants for the derivation of qualified predictions about phenotypic consequences of the observed genetic variation patterns.[7](#cpt690-bib-0007){ref-type="ref"}

Each variant is identified by its genomic coordinate in comparison to a curated reference sequence and is named according to the Human Genome Variation Society nomenclature, which represents the current standard in clinical diagnostics.[8](#cpt690-bib-0008){ref-type="ref"} Furthermore, each SNV, microdeletion, or insertion of \<50 bp that has been observed in multiple genomes is assigned a unique rs number by database‐single‐nucleotide polymorphism, which identifies the respective variant. On the basis of this variant information, a unified and standardized *CYP* allele nomenclature system was established that integrates variant combinations into more accessible and human readable haplotypes designated by "star alleles." This system is made available to the research community through a peer‐reviewed, regularly updated website[9](#cpt690-bib-0009){ref-type="ref"} (<http://www.cypalleles.ki.se>).

In the last decades, a plethora of studies analyzed the links between genetic variants in *CYP* genes and drug responses. Although these studies have provided important information about the frequencies of clinically important *CYP* allele variants and their interethnic differences,[10](#cpt690-bib-0010){ref-type="ref"}, [11](#cpt690-bib-0011){ref-type="ref"} their significance is limited due to their relatively small sample sizes and their focus on small, nonstandardized panels of specific variants of interest. Recently, the increasing dissemination of next‐generation sequencing technologies and the implementation of population‐scale sequencing projects presents a paradigm shift that allows to derive a comprehensive and consolidated overview of the genetic diversity and interethnic variability of *CYP* alleles across worldwide populations.

By integrating exome sequencing data from 56,945 unrelated individuals provided by the Exome Aggregation Consortium with whole genome and linkage information from the 1000 Genomes Project, we derive representative frequencies[12](#cpt690-bib-0012){ref-type="ref"}, [13](#cpt690-bib-0013){ref-type="ref"} of 176 alleles distributed over the 12 *CYP* genes with highest relevance for human drug metabolism in five major populations (Europeans, Africans, South Asians, East Asians, and admixed Americans). The resulting data, to our knowledge, is the most comprehensive overview of *CYP* allele distributions published to date and provides important information for the guidance of population‐specific genotyping strategies.

3. RESULTS {#cpt690-sec-0002}
==========

In this study, we analyzed the prevalence of 176 alleles distributed over the 12 *CYP* genes that jointly account for \>75% of human phase 1 drug metabolism.[4](#cpt690-bib-0004){ref-type="ref"} In *CYP2A6*, we analyzed a total of 23 variants, of which 10 are rare in every population analyzed (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **a**, **Table** [1](#cpt690-tbl-0001){ref-type="table-wrap"}). *CYP2A6\*17* (MAF = 11.2%), *CYP2A6\*23* (MAF = 1.5%), *CYP2A6\*25* (MAF = 1.4%), and *CYP2A6\*28* (MAF = 2%) are only identified in Africans, whereas East Asians are the only population to harbor *CYP2A6\*7* (MAF = 12.9%) and *CYP2A6\*19* (MAF = 1.2%). *CYP2A6\*9* is the most abundant allele in both Asian populations and admixed Americans accounting for 33.3%, 42%, and 49.2% of all variant alleles, respectively, whereas *CYP2A6\*35* is the most abundant variant in Europeans (42.1% of all variants). Frequencies of the deletion allele *CYP2A6\*4* could not be derived from exome sequencing data and, therefore, we used previously published data to approximate *CYP2A6\*4* frequencies in the respective populations.[14](#cpt690-bib-0014){ref-type="ref"}, [15](#cpt690-bib-0015){ref-type="ref"}

###### 

Important variant and allele frequencies of the human *CYP2A6* gene

  Allele   Defining variants         Variant type              Allele frequencies in indicated populations, %   Functional consequence                              
  -------- ------------------------- ------------------------- ------------------------------------------------ ------------------------ ------- ------- ---------- ------------------------------------------------
  \*1      None                      64.6                      65.1                                             30.8                     65.6    71.9    Normal     
  \*2      rs1801272                 Missense (L160H)          2.3                                              0.5                      0       1.1     1.2        Inactive
  \*4      CYP2A6 deleted            1                         1.5                                              17                       7       4       Inactive   
  \*5      rs5031017                 Missense (G479V)          0                                                \<0.1                    0.1     \<0.1   \< 0.1     Inactive
  \*6      rs4986891                 Missense (R128Q)          0                                                0                        \<0.1   0       0          Decreased[a](#cpt690-note-0003){ref-type="fn"}
  \*7      rs5031016                 Missense (I471T)          \<0.1                                            \<0.1                    12.9    0.3     0.3        Decreased[a](#cpt690-note-0003){ref-type="fn"}
  \*8      rs28399468                Missense (R485L)          0.3                                              0.3                      0.3     0.3     0.3        Normal
  \*9      rs28399433                TATA box                  11.1                                             8.3                      23.0    14.4    13.8       Decreased
  \*10     rs5031016, rs28399468     Missense (I471T, R485L)   \<0.1                                            \<0.1                    0.3     0.3     0.3        Decreased[b](#cpt690-note-0004){ref-type="fn"}
  \*14     rs28399435                Missense (S29N)           1.4                                              0.8                      \<0.1   3.5     1.2        
  \*16     rs56256500                Missense (R203S)          0                                                \<0.1                    0       \<0.1   \<0.1      
  \*17     rs28399454                Missense (V365M)          0                                                11.2                     0       0       0.6        Decreased
  \*18     rs1809810                 Missense (Y392F)          1.5                                              0.6                      1.2     1.4     1.1        Decreased[a](#cpt690-note-0003){ref-type="fn"}
  \*19     rs5031016, rs1809810      Missense (I471T, Y392F)   \<0.1                                            \<0.1                    1.2     0.3     0.3        
  \*21     rs6413474                 Missense (K476R)          2.8                                              0.2                      \<0.1   1.9     0.3        Decreased[b](#cpt690-note-0004){ref-type="fn"}
  \*22     rs60605885, rs60563539    Missense (D158E, L160I)   0                                                0                        0       0       \<0.1      
  \*23     rs56256500                Missense (R203C)          0                                                1.5                      0       \<0.1   \<0.1      Decreased
  \*24     rs143731390, rs72549435   Missense (N438Y, V110L)   0                                                0.9                      \<0.1   \<0.1   \<0.1      
  \*25     rs28399440                Missense (F118L)          0                                                1.4                      0       0       0          
  \*26     rs59552350                Missense (S131A)          0                                                0.4                      0       0       0          Decreased
  \*28     rs28399463, rs8192730     Missense (N418D, E419D)   0                                                2                        0.1     \<0.1   0.2        
  \*35     rs143731390               Missense (N438Y)          14.9                                             5.9                      12.8    3.7     4.5        Decreased
  \*39     rs143690364               Missense (V68M)           0                                                \<0.1                    0       \<0.1   0          Decreased[b](#cpt690-note-0004){ref-type="fn"}
  \*41     rs140471703               Missense (R265Q)          0                                                0.2                      \<0.1   0       \<0.1      Inactive

AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians.

For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>.

Indicates alleles whose functionality assessment is based solely on *in vitro* data.

Indicates alleles whose functionality assessment is based solely on *in vivo* data.

![Distribution of the relative contributions of major cytochrome P450 (*CYP*) alleles in European, African, Asian, and American populations. Pie charts showing the relative contribution of common variants in *CYP2A6* (**a**), *CYP2B6* (**b**), *CYP2C8* (**c**), *CYP2C9* (**d**), *CYP2C19* (**e**), *CYP2D6* (**f**), *CYP3A4* (**g**), and *CYP3A5* (**h**) in five major populations. Only variants with a minor allele frequency in the respective population above 1% are shown, whereas all other variants analyzed in this study are summarized as "rare" (grey).](CPT-102-688-g001){#cpt690-fig-0001}

We assessed 25 *CYP2B6* alleles of which 8 are common in at least one population analyzed (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **b**, **Table** [2](#cpt690-tbl-0002){ref-type="table-wrap"}). *CYP2B6\*18* (MAF = 7.1%) and *CYP2B6\*16* (MAF = 6.5%) are restricted to Africans and *CYP2B6\*4* is only common in South Asian populations (MAF = 1.8%). *CYP2B6\*9* is the most abundant allele in all populations analyzed accounting for 40.1--68.6% of all variants in the major populations. *CYP2B6\*5* is highly abundant in Europeans (MAF = 12.8%), less prevalent in Africans (MAF = 2.6%), South Asians (MAF = 8.2%), and admixed Americans (MAF = 4.5%), and virtually absent in East Asians. Notably, the variant rs2279343, which defines *CYP2B6\*4* and is part of *CYP2B6\*6*, was not called in the 1000 Genome Project and, therefore, no linkages with this variant could be computed. Thus, to derive information about the *CYP2B6\*4* and \**6* haplotype frequencies, we estimated the co‐occurrence of the two variants based on previous studies (90% of rs2279343 in combination with rs3745274 as *CYP2B6\*6* and 10% without rs3745274 as *CYP2B6\*4*).[16](#cpt690-bib-0016){ref-type="ref"}

###### 

Important variant and allele frequencies of the human *CYP2B6* gene

  Allele   Defining variants                    Variant type                     Allele frequencies in indicated populations, %   Functional consequence                            
  -------- ------------------------------------ -------------------------------- ------------------------------------------------ ------------------------ ------- ------- -------- ------------------------------------------------
  \*1      None                                 61.1                             37.9                                             75.5                     45      57.8    Normal   
  \*2      rs8192709                            Missense (R22C)                  4.9                                              3.7                      4.5     3.0     2.9      
  \*3      rs45482602                           Missense (S259R)                 \<0.1                                            \<0.1                    0       0.3     0.1      
  \*4      rs2279343                            Missense (K262R)                 0.4                                              0.6                      0.3     1.8     0.3      Increased[b](#cpt690-note-0007){ref-type="fn"}
  \*5      rs3211371                            Missense (R487C)                 12.8                                             2.6                      0.1     8.2     4.5      
  \*6      rs2279343, rs3745274                 Missense (K262R, Q172H)          3.4                                              5.8                      2.7     15.8    3        Decreased
  \*7      rs2279343, rs3745274, rs3211371      Missense (K262R, Q172H, R487C)   0                                                0                        0       0       0        
  \*8      rs12721655                           Missense (K139E)                 \<0.1                                            \<0.1                    0       \<0.1   \<0.1    Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*9      rs3745274                            Missense (Q172H)                 15.6                                             30.9                     16      23.2    29       
  \*10     rs8192709, rs34883432                Missense (R22C, Q21L)            \<0.1                                            \<0.1                    0       0.1     0.3      
  \*11     rs35303484                           Missense (M46V)                  \<0.1                                            0.1                      0       0.2     0.1      Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*12     rs36060847                           Missense (G99E)                  0                                                \<0.1                    0       0       \<0.1    Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*13     rs2279343, rs3745274, rs12721655     Missense (K262R, Q172H, K139E)   \<0.1                                            \<0.1                    0       \<0.1   \<0.1    
  \*14     rs35773040                           Missense (R140Q)                 0.5                                              \<0.1                    \<0.1   0.3     \<0.1    Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*15     rs35979566                           Missense (I391N)                 0.2                                              0.2                      0       \<0.1   0.2      Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*16     rs2279343 & rs28399499               Missense (I328T)                 0                                                6.5                      0       \<0.1   0.3      Decreased
  \*17     rs33973337, rs33980385, rs33926104   Missense (T26S, D28G, R29T)      0                                                \<0.1                    0       0       0        
  \*18     rs28399499                           Missense (I328T)                 0                                                7.1                      0       \<0.1   0.3      Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*19     rs34826503                           Missense (R336C)                 0                                                0.3                      \<0.1   0       \<0.1    Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*20     rs36056539                           Missense (T168I)                 0                                                0.1                      0       0       \<0.1    Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*21     rs35010098                           Missense (P428T)                 0                                                \<0.1                    0       0       0        Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*22     rs34223104                           Regulatory                       0.9                                              3.6                      0.2     1.8     0.7      Increased[a](#cpt690-note-0006){ref-type="fn"}
  \*23     rs3211369                            Missense (M459V)                 0                                                0                        \<0.1   \<0.1   0        
  \*26     rs2279343, rs3745274, rs3826711      Missense (K262R, Q172H, P167A)   0                                                0                        0.5     0       0        Decreased[b](#cpt690-note-0007){ref-type="fn"}
  \*27     rs36079186                           Missense (M198T)                 0                                                0.2                      0       0.1     \<0.1    Decreased[a](#cpt690-note-0006){ref-type="fn"}
  \*28     rs34097093                           Stop‐gain (R378X)                0                                                \<0.1                    0       0       \<0.1    Inactive

AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians.

For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>.

Indicates alleles whose functionality assessment is based solely on *in vitro* data.

Indicates alleles whose functionality assessment is based solely on *in vivo* data.

Only three of nine *CYP2C8* alleles are common in at least one of the super populations assessed (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **c**, **Table** [3](#cpt690-tbl-0003){ref-type="table-wrap"}). In Europeans and admixed American populations, only *CYP2C8\*3* (MAF = 11.2% and 6.7% in Europeans and Americans, respectively) and *CYP2C8\*4* (MAF = 6% and 2.3% in Europeans and Americans, respectively) are common. In contrast, *CYP2C8\*2* constitutes the most prevalent allele in Africans (MAF = 15.9%, corresponding to 82.9% of all variant *CYP2C8* alleles in Africans) but is not detected in Europeans and East Asians. Surprisingly, *CYP2C8* is largely invariant in populations in East Asia and no variant with an allele frequency \>1% was detected. This is in pronounced contrast to South Asian populations, in which the \**2* (MAF = 1.9%), \**3* (MAF = 4%), and \**4* (MAF = 1.5%) alleles are common.

###### 

Important variant and allele frequencies of important pharmacogenes in the human *CYP2C* family

  Allele    Defining variants        Variant type                 Allele frequencies in indicated populations, %   Functional consequence                             
  --------- ------------------------ ---------------------------- ------------------------------------------------ ------------------------ ------- -------- -------- ------------------------------------------------
  CYP2C8                                                                                                                                                              
  \*1       None                     82.8                         80.8                                             98.7                     92.6    90.1     Normal   
  \*2       rs11572103               Missense (I269F)             0                                                15.9                     0       1.9      0.9      Decreased[a](#cpt690-note-0009){ref-type="fn"}
  \*3       rs10509681, rs11572080   Missense (K399R, R139K)      11.2                                             2.1                      \<0.1   4        6.7      Decreased[a](#cpt690-note-0009){ref-type="fn"}
  \*4       rs1058930                Missense (I264M)             6.0                                              1.1                      0       1.5      2.3      Decreased[a](#cpt690-note-0009){ref-type="fn"}
  \*5       rs72558196               Frameshift                   0                                                0                        0.2     0        0        Inactive
  \*6       rs142886225              Missense (G171S)             0                                                0                        0.5     0        0        Normal
  \*7       rs72558195               Stop‐gain (R186X)            0                                                \<0.1                    \<0.1   \<0.1    0        Inactive
  \*11      rs78637571               Stop‐gain (E274X)            0                                                0                        0.4     0        \<0.1    Inactive
  \*12      rs3832694                Inframe deletion (461delV)   0                                                0                        \<0.1   0        0        
  \*14      rs188934928              Missense (A238P)             0                                                0                        0.1     \<0.1    0        Decreased[a](#cpt690-note-0009){ref-type="fn"}
  CYP2C9                                                                                                                                                              
  \*1       None                     81.8                         78.4                                             95.7                     81.3    88.9     Normal   
  \*2       rs1799853                Missense (R144C)             11.7                                             2.4                      \<0.1   4.6      6.6      Decreased[a](#cpt690-note-0009){ref-type="fn"}
  \*3       rs1057910                Missense (I359L)             5.6                                              1.3                      3.4     11.3     3.6      Decreased
  \*4       rs56165452               Missense (I359T)             0                                                \<0.1                    0       0        0        
  \*5       rs28371686               Missense (D360E)             0                                                1.3                      0       0        \<0.1    Decreased
  \*6       rs9332131                Frameshift                   0                                                1                        0       0        \<0.1    Inactive
  \*7       rs67807361               Missense (L19I)              0                                                0                        0       0.3      0        
  \*8       rs7900194                Missense (R150H)             0                                                5.6                      \<0.1   \<0.1    0.2      Decreased
  \*9       rs2256871                Missense (H251R)             0                                                7.5                      \<0.1   \<0.1    0.2      
  \*11      rs28371685               Missense (R335W)             0.5                                              2.1                      \<0.1   0.2      0.2      Decreased
  \*12      rs9332239                Missense (P489S)             0.2                                              \<0.1                    0       \<0.1    0.1      
  \*13      rs72558187               Missense (L90P)              0                                                0                        0.2     0        0        Decreased
  \*14      rs72558189               Missense (R125H)             0                                                \<0.1                    \<0.1   2.0      \<0.1    
  \*15      rs72558190               Stop‐gain (S162X)            0                                                0                        \<0.1   0        0        
  \*16      rs72558192               Missense (T299A)             0                                                0                        0.3     0        0        
  \*29      rs182132442              Missense (P279T)             0.1                                              0                        0.2     \<0.1    \<0.1    
  \*30      rs781583846              Missense (A477T)             \<0.1                                            \<0.1                    \<0.1   \<0.1    \<0.1    
  \*31      rs57505750               Missense (I327T)             0                                                0.2                      0       0        0        
  \*33      rs200183364              Missense (R132Q)             0                                                \<0.1                    0       \<0.1    0        
  \*36      rs114071557              Start lost                   0                                                0.2                      \<0.1   \<0.1    \<0.1    
  \*42      rs12414460               Missense (R124Q)             \<0.1                                            \<0.1                    \<0.1   0        \<0.1    
  \*44      rs200965026              Missense (T130M)             0                                                0                        \<0.1   0        \<0.1    
  \*45      rs199523631              Missense (R132W)             \<0.1                                            \<0.1                    0       \< 0.1   \<0.1    
  CYP2C19                                                                                                                                                             
  \*1       None                     59.2                         44.5                                             60.5                     51.9    77       Normal   
  \*2       rs4244285                Splicing defect              18.3                                             18.1                     31.0    34.0     10.1     Inactive
  \*3       rs4986893                Stop‐gain (W212X)            \<0.1                                            \<0.1                    6.7     0.4      \<0.1    Inactive
  \*4       rs28399504               Start lost                   0                                                \<0.1                    \<0.1   \<0.1    0.2      Inactive
  \*5       rs56337013               Missense (R433W)             0                                                0                        0       \<0.1    0        Inactive
  \*6       rs72552267               Missense (R132Q)             0                                                0                        \<0.1   0        \<0.1    Inactive
  \*7       rs72558186               Splicing defect              0                                                0                        0       \<0.1    0        Inactive[b](#cpt690-note-0010){ref-type="fn"}
  \*8       rs41291556               Missense (W120R)             \<0.1                                            \<0.1                    0       \<0.1    \<0.1    Inactive
  \*9       rs17884712               Missense (R144H)             0                                                1.2                      0       \<0.1    \<0.1    
  \*10      rs6413438                Missense (P227L)             0                                                0.4                      \<0.1   0        \<0.1    Decreased[a](#cpt690-note-0009){ref-type="fn"}
  \*12      rs55640102               Stop‐lost (X491C)            0                                                \<0.1                    0       0        0        Decreased[a](#cpt690-note-0009){ref-type="fn"}
  \*13      rs17879685               Missense (R410C)             0                                                1.6                      0       \<0.1    0.1      
  \*15      rs17882687               Missense (I19L)              0                                                2.0                      0       \<0.1    \<0.1    
  \*16      rs192154563              Missense (R442C)             0                                                \<0.1                    0       \<0.1    0        
  \*17      rs12248560               Regulatory                   22.4                                             23.5                     1.5     13.6     12.0     Increased
  \*22      rs140278421              Missense (R186P)             0                                                0.1                      0       0        \<0.1    
  \*23      rs118203756              Missense (G91R)              0                                                0                        \<0.1   0        0        
  \*24      rs118203757              Missense (R335Q)             0                                                \<0.1                    0       \<0.1    \<0.1    
  \*25      rs118203759              Missense (F448L)             0                                                0                        0       0        0        
  \*27      rs7902257                Regulatory                   0.1                                              8.3                      0.1     0        0.3      Decreased[a](#cpt690-note-0009){ref-type="fn"}

AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians.

For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>.

Indicates alleles whose functionality assessment is based solely on *in vitro* data.

Indicates alleles whose functionality assessment is based solely on *in vivo* data.

Genetic variability of *CYP2C9* is dominated by the \**2* allele in Europeans (MAF = 11.7%) and admixed Americans (MAF = 6.6%), whereas the major alleles in Asian populations and Africans are \**3* (MAF = 3.4% in East Asians and 11.3% in South Asians) and \**9* (MAF = 7.5%), respectively (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **d**, **Table** [3](#cpt690-tbl-0003){ref-type="table-wrap"}). The spectrum of *CYP2C9* variants is highly population‐specific with *CYP2C9\*5*, \**6*, \**8*, \**9*, and \**11* being restricted to African populations and *CYP2C9\*14* being almost uniquely identified in South Asians.

Overall, we analyzed 19 variants in *CYP2C19*, of which *CYP2C19\*17*, and *CYP2C19\*2* are the major variants (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **e**, **Table** [3](#cpt690-tbl-0003){ref-type="table-wrap"}). In Europeans, Africans, and admixed Americans, the \**17* promoter variant, which results in increased *CYP2C19* transcription most probably due to the modulation of GATA4 binding,[17](#cpt690-bib-0017){ref-type="ref"}, [18](#cpt690-bib-0018){ref-type="ref"} is most abundant, accounting for 42--55% of all variant alleles, whereas the \**2* loss‐of‐function variant that causes aberrant splicing is most prevalent in Asian populations (78.5% and 70.7% of all variant alleles in East and South Asians, respectively). Further *CYP2C19* alleles are highly specific to individual populations. The stop‐gain variant *CYP2C19\*3* is abundant exclusively in East Asians (MAF = 6.7%), whereas *CYP2C19\*9* (MAF = 1.2%), \**13* (MAF = 1.6%), \**15* (MAF = 2%), and \**27* (MAF = 8.3%) are restricted to Africans.

The *CYP2D6* gene locus is complex and highly polymorphic, harboring a multitude of common genetic variants with clinical importance (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **f**, **Table** [4](#cpt690-tbl-0004){ref-type="table-wrap"}). The *CYP2D6\*2* allele is most abundant in European, African, South Asian, and admixed American populations and the most prevalent haplotype worldwide. The variant defining *CYP2D6\*4* (rs3892097), which causes a splicing defect and inactivation of the *CYP2D6* gene product, is present in all analyzed populations with MAFs between 11.6% and 15.7%, except in East Asians in which the frequency of the allele was \<1%. *CYP2D6\*10* is almost exclusively found in African, South Asian, and, most notably, East Asian populations in which \**10* constitutes the most common *CYP2D6* allele (MAF = 58.7%). *CYP2D6\*3* (MAF = 4.1%) and *CYP2D6\*6* (MAF = 2.2%) are only found in individuals of European ancestry. *CYP2D6\*17* (MAF = 19.7%), *CYP2D6\*29* (MAF = 9.2%), and *CYP2D6\*43* (MAF = 2%) are distinctive haplotypes for Africans and *CYP2D6\*14* was only found in East Asian populations (MAF = 1.6%). As quantification of certain genetic rearrangements can be difficult to assess with short‐read sequencing based methodologies, we included frequency information for the duplicated alleles *CYP2D6\*1xN* and *CYP2D6\*2xN* as well as for the deletion *CYP2D6\*5* from the published literature. Duplications of *CYP2D6* occur with frequencies of 1--2% in whites and Asians but are more common in certain African populations, in which their frequency can be up to 29%, as previously reported.[19](#cpt690-bib-0019){ref-type="ref"}, [20](#cpt690-bib-0020){ref-type="ref"} For deletions of *CYP2D6*, we assumed frequencies between 1% and 7% for the analyzed populations based on previous extensive meta‐analyses.[20](#cpt690-bib-0020){ref-type="ref"}

###### 

Important variant and allele frequencies of the human *CYP2D6* gene

  Allele   Defining variants                            Variant type                            Allele frequencies in indicated populations, %   Functional consequence                               
  -------- -------------------------------------------- --------------------------------------- ------------------------------------------------ ------------------------ ------- ------- ----------- ------------------------------------------------
  \*1      None                                         33.1                                    9.3                                              13.6                     25.8    40.2    Normal      
  \*1xN    Amplification of \*1                         1                                       3.3                                              1                        0.5     0.5     Increased   
  \*2      rs16947, rs1135840                           Missense (R296C, S486T)                 34.3                                             26.7                     14      36.2    32.7        Normal
  \*2xN    Amplification of \*2                         1.3                                     6                                                1                        1       0.5     Increased   
  \*3      rs35742686                                   Frameshift                              4.1                                              0.3                      0       0.1     0.3         Inactive
  \*4      rs3892097                                    Splicing defect                         15.5                                             11.9                     0.4     11.6    15.7        Inactive
  \*5      CYP2D6 deleted                               3                                       4                                                6.5                      2       3       Inactive    
  \*6      rs5030655                                    Frameshift                              2.2                                              0.3                      0       0.1     0.4         Inactive
  \*7      rs5030867                                    Missense (H324P)                        0                                                \<0.1                    0       0.8     \<0.1       Inactive[b](#cpt690-note-0013){ref-type="fn"}
  \*8      rs5030865                                    Stop‐gain (G169X)                       0                                                \<0.1                    0       \<0.1   0           Inactive
  \*9      rs5030656                                    Inframe deletion (K281del)              1.6                                              0.4                      0       0.2     1.3         Decreased
  \*10     rs1065852, rs1135840                         Missense (P34S, S486T)                  0.2                                              3.2                      58.7    6.5     0           Decreased
  \*11     rs201377835                                  Splicing defect                         0                                                \<0.1                    0       0       0           Inactive[b](#cpt690-note-0013){ref-type="fn"}
  \*12     rs5030862                                    Missense (G42R)                         0                                                \<0.1                    0       0       0           Inactive
  \*14     rs5030865                                    Missense (G169R)                        0                                                0                        1.6     \<0.1   0           Inactive
  \*17     rs16947, rs28371706                          Missense (R296C, T107I)                 \<0.1                                            19.7                     0       0.1     0.7         Decreased
  \*29     rs16947, rs1135840, rs61736512, rs59421388   Missense (R296C, S486T, V136I, V338M)   0                                                9.2                      \<0.1   \<0.1   0.4         Decreased
  \*33     rs28371717                                   Missense (A237S)                        0.7                                              0.2                      0       0.7     0.1         Normal
  \*41     rs28371725                                   Splicing defect                         3.0                                              3.0                      3.0     13.5    3.5         Decreased
  \*42     rs72549346                                   Frameshift                              0                                                0.2                      0       0       \<0.1       Inactive
  \*43     rs28371696                                   Missense (R26H)                         \<0.1                                            2.0                      \<0.1   0.8     0.2         
  \*53     rs1135822, rs1135823                         Missense (F120I, A122S)                 0                                                \<0.1                    \<0.1   \<0.1   0.5         Increased[a](#cpt690-note-0012){ref-type="fn"}
  \*62     rs730882171                                  Missense (R441C)                        \<0.1                                            \<0.1                    \<0.1   \<0.1   \<0.1       Inactive

AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians.

For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>.

Indicates alleles whose functionality assessment is based solely on *in vitro* data.

Indicates alleles whose functionality assessment is based solely on *in vivo* data.

*CYP3A4*, which metabolizes around one‐third of all medications[4](#cpt690-bib-0004){ref-type="ref"} as well as endogenous steroid hormones, harbors only few common genetic variants (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **g**, **Table** [5](#cpt690-tbl-0005){ref-type="table-wrap"}). Of the 19 *CYP3A4* variants we assessed, only 5 were common in at least one of the major populations. In Europeans and admixed Americans, *CYP3A4\*22* is the major allele (MAF = 5% and 2.6%, respectively) with \**3* and \**2* contributing to the genetic variability in the former. In contrast, *CYP3A4\*15* (MAF = 2.5%) and *CYP3A4\*18* (MAF = 1.9%) constitute the only common *CYP3A4* alleles in Africans and East Asians, respectively. In South Asian populations, no common *CYP3A4* variant with MAFs \>1% are present.

###### 

Important variant and allele frequencies of important pharmacogenes in the human *CYP3A* family

  Allele   Defining variants   Variant type        Allele frequencies in indicated populations (in %)   Functional consequence                            
  -------- ------------------- ------------------- ---------------------------------------------------- ------------------------ ------- ------- -------- ------------------------------------------------
  CYP3A4                                                                                                                                                  
  \*1      None                91.5                96.6                                                 97                       99.1    96.9    Normal   
  \*2      rs55785340          Missense (S222P)    1.1                                                  0                        0       0       0        
  \*3      rs4986910           Missense (M445T)    2.1                                                  0.1                      0       0       0.2      
  \*4      rs55951658          Missense (I118V)    0                                                    0                        0.6     \<0.1   \<0.1    
  \*5      rs55901263          Missense (P218R)    0                                                    0                        \<0.1   0       0        
  \*6      rs4646438           Frameshift          0                                                    0                        0.2     \<0.1   \<0.1    
  \*7      rs56324128          Missense (G56D)     0.1                                                  0                        0       0       0        
  \*8      rs72552799          Missense (R130Q)    0.1                                                  0                        0       \<0.1   \<0.1    Decreased[a](#cpt690-note-0015){ref-type="fn"}
  \*9      rs72552798          Missense (V170I)    0                                                    0                        0       0       \<0.1    
  \*10     rs4986908           Missense (D174H)    \<0.1                                                0.2                      \<0.1   0.1     \<0.1    
  \*11     rs67784355          Missense (T363M)    0                                                    \<0.1                    \<0.1   \<0.1   0        Decreased[a](#cpt690-note-0015){ref-type="fn"}
  \*12     rs12721629          Missense (L373F)    0                                                    0.3                      0       \<0.1   \<0.1    
  \*13     rs4986909           Missense (P416L)    0                                                    0                        0       0       \<0.1    Decreased[a](#cpt690-note-0015){ref-type="fn"}
  \*15     rs4986907           Missense (R162Q)    0                                                    2.5                      0       \<0.1   0.2      
  \*16     rs12721627          Missense (T185S)    0                                                    0                        0.1     0       0        Decreased[a](#cpt690-note-0015){ref-type="fn"}
  \*18     rs28371759          Missense (L293P)    0                                                    0.2                      1.9     0       \<0.1    Decreased
  \*19     rs4986913           Missense (P467S)    0                                                    0                        0       \<0.1   0        
  \*20     rs67666821          Frameshift          0                                                    \<0.1                    0       0       \<0.1    Inactive
  \*22     rs35599367          Intronic            5.0                                                  \<0.1                    0       0.6     2.6      Decreased[b](#cpt690-note-0016){ref-type="fn"}
  \*26     rs138105638         Stop‐gain (R268X)   0                                                    \<0.1                    0       \<0.1   \<0.1    Inactive
  CYP3A5                                                                                                                                                  
  \*1      None                5.3                 56.3                                                 27.7                     33.2    17.5    Normal   
  \*2      rs28365083          Missense (T398N)    0.1                                                  \<0.1                    0       0       \<0.1    
  \*3      rs776746            Splicing defect     94.3                                                 18.0                     71.3    66.8    79.7     Inactive
  \*4      rs56411402          Missense (Q200R)    0                                                    0                        0.3     0       0        
  \*5      rs55965422          Splicing defect     0                                                    0                        0.7     \<0.1   0        
  \*6      rs10264272          Splicing defect     0.3                                                  15.4                     0       0       2.3      Inactive
  \*7      rs41303343          Frameshift          0                                                    10.3                     \<0.1   \<0.1   0.4      
  \*8      rs55817950          Missense (R28C)     0                                                    0                        \<0.1   0       0        Decreased[a](#cpt690-note-0015){ref-type="fn"}

AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians.

For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>.

Indicates alleles whose functionality assessment is based solely on *in vitro* data.

Indicates alleles whose functionality assessment is based solely on *in vivo* data.

The *CYP3A5* locus is highly variable across all human populations, yet harbors only few common genetic variants (**Figure** [1](#cpt690-fig-0001){ref-type="fig"} **h**, **Table** [5](#cpt690-tbl-0005){ref-type="table-wrap"}). *CYP3A5\*3*, an SNV causing alternative splicing and protein truncation, results in the almost complete abrogation of *CYP3A5* activity.[21](#cpt690-bib-0021){ref-type="ref"} This allele is highly abundant in South Asians, East Asians, admixed Americans, and Europeans and constitutes the major allele with frequencies of 66.8%, 71.3%, 79.7%, and 94.3%, respectively. In contrast, the variant spectrum of *CYP3A5* in Africans is distinctly different. Whereas the frequency of *CYP3A5\*3* is much lower (MAF = 18%), Africans also harbor the *CYP3A5\*6* (MAF = 15.4%) and \**7* (MAF = 10.3%) alleles with high frequencies.

Besides those *CYP* genes with the highest pharmacogenetic importance, we also analyzed the allelic variant profiles of *CYP1A1*, *CYP1A2*, *CYP2E1*, and *CYP4F2*, genes with a lower extent of functionally important polymorphisms. The frequencies of the respective alleles for these genes can be found in **Supplementary Tables S1--S4**.

Among the pharmacogenetically most important CYPs, *CYP2D6* is the most variable with cumulative allele frequencies between 59.8% in admixed Americans and 90.7% in Africans (**Figure** [2](#cpt690-fig-0002){ref-type="fig"} **a**). In contrast, *CYP3A4* is the most conserved gene with \<10% of alleles harboring identified variant haplotypes. Notably, the largest differences in variability between populations are observed for *CYP3A5* (cumulative allele frequencies 44--95%), *CYP2A6* (28--69%), and *CYP2B6* (24--62%).

![The genetic variability and their functional consequences differ drastically between major cytochrome P450 (*CYP*) genes and across populations. (**a**) Cumulative frequencies of all major variant alleles in Europeans (EUR; blue), Africans (AFR; red), East Asians (EAS; green), South Asians (SAS; purple), and admixed Americans (AMR; turquoise) are shown for each major *CYP* gene. Overall, *CYP2D6* constitutes the most variable gene, whereas *CYP3A4* is most conserved. (**b**) The expected functional consequences of allelic distributions across world populations are shown. Frequencies of haplotypes with decreased (blue), increased (green), and normal (red) functionality, as defined in **Tables** [1](#cpt690-tbl-0001){ref-type="table-wrap"}, [2](#cpt690-tbl-0002){ref-type="table-wrap"}, [3](#cpt690-tbl-0003){ref-type="table-wrap"}, [4](#cpt690-tbl-0004){ref-type="table-wrap"}, [5](#cpt690-tbl-0005){ref-type="table-wrap"}, were aggregated for each gene and population, revealing the spectrum of functional variability in major world populations.](CPT-102-688-g002){#cpt690-fig-0002}

Importantly, aggregation of allelic frequency data by their functional consequences revealed major differences in predicted functionality patterns across the populations. Functionally impaired *CYP2A6* alleles are primarily found in East Asian populations where 67.5% of alleles are defective, whereas the frequencies of such alleles pivot around 30% in the other populations analyzed (**Figure** [2](#cpt690-fig-0002){ref-type="fig"} **b**). Although the *CYP2B6* locus is highly variable, the fraction of alleles that result in functional consequences is considerably smaller. In Africans and South Asians, around 20.5% and 16.7% of *CYP2B6* alleles are expected to result in decreased activity, respectively. Between 7% and 20% of *CYP2C8* and *CYP2C9* alleles exhibit decreased functionality across major world populations, with the exception of East Asians for which \<1% and 4% of functional *CYP2C8* and *CYP2C9* variants are observed, respectively. Of the genes analyzed, *CYP2C19* harbors the highest frequency of increased activity alleles (*CYP2C19\*17*), ranging from 1.5% in East Asians to 22.4% and 23.5% in Europeans and Africans, respectively.

*CYP2D6* constitutes the most complex *CYP* locus known to harbor a large number of distinctly different common haplotypes with important clinical implications. In this study, we found that between 25.3% and 70.3% of analyzed alleles contained variant combinations with no or reduced functional activity. Furthermore, the *CYP2D6* gene is commonly duplicated in 1.5--9.3% of alleles, causing increased metabolic activity toward the respective substrates. The enzymes encoded by the two major genes in the *CYP3A* family, *CYP3A4* and *CYP3A5*, exhibit similar metabolic capabilities[22](#cpt690-bib-0022){ref-type="ref"} but drastically different variation profiles. Although *CYP3A4* harbored only few common functional variants, the high prevalence of *CYP3A5\*3* causing alternative splicing resulted in the major fraction of alleles showing severely reduced functional activity (**Figure** [2](#cpt690-fig-0002){ref-type="fig"} **b**).

4. DISCUSSION {#cpt690-sec-0003}
=============

To date, a multitude of studies have analyzed the frequencies of *CYP* alleles in populations around the world. Yet, most studies analyzed only the prevalence of a selected subset of SNVs in a particular gene and only in one or few subpopulations of relatively small sample size. To overcome these limitations, a variety of studies consolidated frequency information from multiple studies to allow a broader overview of the true frequencies between populations. Fricke--Galindo *et al*.[23](#cpt690-bib-0023){ref-type="ref"} performed a meta‐analysis integrating variant frequency data of seven *CYP2C19* alleles from 138 studies. Furthermore, a recent extensive meta‐analysis of 173 reports revealed the spectrum of allele frequencies and predicted functional consequences across major populations for *CYP2D6*.[20](#cpt690-bib-0020){ref-type="ref"} However, meta‐analyses are limited to a small number of haplotypes for which several reports are available and integration of multiple studies can be problematic due to differences in underlying genotyping strategies and differentially designed assay panels.[24](#cpt690-bib-0024){ref-type="ref"} For instance, in a study by Griese *et al*.,[25](#cpt690-bib-0025){ref-type="ref"} which was included in the highlighted *CYP2D6* meta‐analysis, the prevalence of 16 *CYP2D6* haplotypes were analyzed in a Ghanaian population by allele‐specific polymerase chain reaction, including the normactive *CYP2D6\*2* haplotype, which is defined by two variants (rs16947 and rs1135840).[25](#cpt690-bib-0025){ref-type="ref"} Yet, in combination with two additional SNVs (rs61736512 and rs59421388), which were not assessed in the respective study, these two variants constitute *CYP2D6\*29*, a haplotype that exhibits reduced activity. Thus, the \**2* haplotype, as designated by Griese *et al*.,[25](#cpt690-bib-0025){ref-type="ref"} likely encompasses the less active \**29* allele, confounding the reported haplotype and activity frequencies.

To overcome these limitations, in this study, we analyzed uniform next‐generation sequencing data ensuring that variant information is fully consistent and compatible. Our analyses reveal the drastic extent of genetic variability between major populations, which entail phenotypic consequences on the level of differential metabolic activity profiles and incentivizes population‐adjusted pharmacogenetic genotyping strategies. Notably though, there are additional layers of genetic variability between specific subpopulations within the aggregated superpopulations that we analyzed, as has been shown, for instance, for *CYP2D6* gene duplications and the distribution of the *CYP2C19\*17* allele within Europe, which occur with a strong south‐north and west‐east gradient, respectively.[20](#cpt690-bib-0020){ref-type="ref"}, [23](#cpt690-bib-0023){ref-type="ref"} Overall, Africans constitute the most heterogeneous superpopulation, as exemplified by large differences in *CYP2D6\*5*, *CYP2D6\*29*, and *CYP3A5\*3* frequencies that vary among 3--17%, 2--20%, and 4--95% between subpopulations, respectively.[26](#cpt690-bib-0026){ref-type="ref"}, [27](#cpt690-bib-0027){ref-type="ref"} Therefore, higher resolution maps across the subpopulations will add clinically useful information and we expect that such datasets will be available in the near future when the many current whole genome analyses projects have been published.

CYP2A6 is the main enzyme involved in nicotine metabolism and is also involved in the bioactivation of procarcinogens from tobacco smoke. Previous studies showed that CYP2A6 deficiency resulted in reduced nicotine dependence[28](#cpt690-bib-0028){ref-type="ref"} as well as a markedly reduced lung cancer risk (odds ratio = 0.23).[29](#cpt690-bib-0029){ref-type="ref"} Given the high prevalence of functionally deficient *CYP2A6* alleles in East Asian populations (67.5%; **Figure** [2](#cpt690-fig-0002){ref-type="fig"} **b**), these data corroborate that the genetic contribution to nicotine addiction as well as the risk to develop pulmonary lesions is reduced in these populations.

CYP2B6 and CYP2A6 are the key enzymes responsible for metabolism of the antiretroviral efavirenz, and deficiency of these enzymes can result in increased systemic exposure.[30](#cpt690-bib-0030){ref-type="ref"}, [31](#cpt690-bib-0031){ref-type="ref"}, [32](#cpt690-bib-0032){ref-type="ref"} Importantly, significant associations between reduced CYP2B6 activity and neurological symptoms were described for pediatric as well as adult patients, indicating that *CYP2B6* genotyping might reveal biomarkers for increased risk of efavirenz toxicity particularly in African populations in which *CYP2B6* deficient alleles are most frequent.[33](#cpt690-bib-0033){ref-type="ref"}, [34](#cpt690-bib-0034){ref-type="ref"} Notably, no clear effect on CYP2B6 functionality has been demonstrated for *CYP2B6\*5* and *CYP2B6\*9*, the most abundant *CYP2B6* variant alleles in Europeans and admixed Americans. Interestingly, *CYP2B6\*5* apparently results in significantly reduced expression levels of CYP2B6 *in vitro*, however, without altering efavirenz metabolism suggesting increased specific activity of the gene product, which compensates for the reduced expression levels.[35](#cpt690-bib-0035){ref-type="ref"} In agreement with these *in vitro* findings, no effect of *CYP2B6\*5* on efavirenz pharmacokinetics was observed *in vivo*.[36](#cpt690-bib-0036){ref-type="ref"} Thus, interrogating the functional effects of these alleles using a variety of CYP2B6 substrates will be an important task for future studies to allow for a more accurate translation of *CYP2B6* genetic variability into functional activity profiles.

CYP2C8 is involved in the metabolism of a multitude of chemically diverse medications, including nonsteroidal anti‐inflammatory drugs, thiazolidinediones, and chemotherapeutic agents. Importantly, *CYP2C8* alleles causing impaired activity have been implicated in reduced clearance and increased exposure to paclitaxel, which correlates with higher incidences of paclitaxel‐induced neuropathies.[37](#cpt690-bib-0037){ref-type="ref"}, [38](#cpt690-bib-0038){ref-type="ref"} In light of the distribution of *CYP2C8* deficient alleles, *CYP2C8* genotyping might be a viable option in Africans and Europeans in which 19.2% and 17.2% of *CYP2C8* alleles are expected to exhibit reduced functionality, respectively. In contrast, genotyping in East Asians cannot be recommended due to the low frequencies of deficient *CYP2C8* variants (\<1%).

Extremely slow clearance of phenytoin and increased risk of neurotoxicity has been observed in patients homozygous for *CYP2C9*‐deficient alleles.[39](#cpt690-bib-0039){ref-type="ref"} Furthermore, CYP2C9 deficiency is linked to bleeding complications upon treatment with warfarin and other anticoagulants. Together with age, body‐surface area, and polymorphisms in *VKORC1*, *CYP2C9* variants explain 50% of the interindividual variability in dose requirements[40](#cpt690-bib-0040){ref-type="ref"} and a recent prospective trial showed that dosing guided by *CYP2C9* and *VKORC1* genotypes can increase the time in the therapeutic range and decrease the number of adverse events with atrial fibrillation or venous thromboembolism.[41](#cpt690-bib-0041){ref-type="ref"} These findings suggest that due to the distribution of CYP2C9 deficiencies in major populations, Europeans, Africans, and South Asians might be at increased risks of phenytoin toxicity as well as complications due to warfarin treatment.

The arguably most extensively studied *CYP* gene is *CYP2D6*, which metabolizes around 25% of all drugs in clinical use. Genetic polymorphisms that result in increased CYP2D6 metabolic capacities, primarily observed in Africans, have been linked to decreased treatment response observed for the treatment with tricyclic antidepressants,[42](#cpt690-bib-0042){ref-type="ref"} increased incidences of respiratory depression after tramadol treatment,[43](#cpt690-bib-0043){ref-type="ref"} opioid intoxication after codeine treatment with concomitant CYP3A4 inhibition, and transient reduction in renal functionality.[44](#cpt690-bib-0044){ref-type="ref"} In contrast, patients with reduced functionality *CYP2D6* alleles, which are found with highest frequencies in East Asian (70.3%) and African populations (52.5%), bear an increased risk to develop hepatotoxicity upon treatment with the antianginal agent perhexiline,[45](#cpt690-bib-0045){ref-type="ref"} metoclopramide‐induced acute dystonic reactions,[46](#cpt690-bib-0046){ref-type="ref"} and adverse drug reactions caused by the antipsychotic risperidone.[47](#cpt690-bib-0047){ref-type="ref"}

The functional *CYP3A5\*1* variant has recently been implicated in decreased safety of sunitinib treatment in patients with metastatic renal cell carcinoma.[48](#cpt690-bib-0048){ref-type="ref"} The splice variant rs776746 that results in *CYP3A5* deficiency (*CYP3A5\*3*) was found at very high frequencies in European populations (94.3%), whereas the combined prevalence of the inactive \**3* and \**6* alleles in Africans was only 33.4%. These results suggest that Africans might be at increased risks of sunitinib toxicity, incentivizing the clinical investigation of outcomes of treatment with lower sunitinib doses in these populations.

The CYP star allele nomenclature system provides a standardized nomenclature system, which facilitates scientific exchange and promotes the understanding of pharmacogenetic variability by nonpharmacogeneticists, such as clinicians. In this nomenclature system, genetic variants within the *CYP* genes that exert functional effects or cause unique amino acid substitutions are designated with a star (\*) number. Yet, for some complex loci, interpretations of the star allele nomenclature can be impeded by intricate haplotype structures and the inclusion of different nonfunctional variants in the allelic definitions, frequently resulting in the use of different genotyping strategies for the analyses of CYP allelic variants. However, it is of importance to interrogate a sufficiently large number of single‐nucleotide polymorphisms in order to correctly assign a specific star allele. For instance, *CYP2D6\*2* cannot be called solely based on the presence of the defining variants rs16947 and rs1135840. Rather, other variants that are commonly detected in linkage with this variant combination, such as rs3892097 (*CYP2D6\*4*) and rs5030865 (*CYP2D6\*14*), also need to be excluded. Furthermore, due to the large number of extensive next‐generation sequencing projects, many novel rare variants are detected, which are important modulators of patients\' response to pharmacological treatment but cannot be subsumed under existing star alleles.[49](#cpt690-bib-0049){ref-type="ref"} Thus, although the star allele nomenclature has considerable advantages for simple descriptions of the variant *CYP* alleles, it cannot be used to define the true global variability of all different *CYP* alleles.

In summary, our analyses reveal the large extent of genetic variability between major populations and can serve as a powerful resource for the worldwide distribution of *CYP* allele frequencies. Furthermore, these findings underscore the need to consider population‐specific genetic backgrounds when conducting pharmacogenetic analyses and clinical trials.

5. METHODS {#cpt690-sec-0004}
==========

5.1. Allele frequency data {#cpt690-sec-0005}
--------------------------

Frequency information of exonic variants was obtained from Exome Aggregation Consortium, which integrated 14 large‐scale sequencing efforts encompassing in total sequences of 56,945 unrelated individuals from five major populations, encompassing 33,370 Europeans, 5,203 Africans and African Americans, 4,327 East Asians, 8,256 South Asians, and 5,789 admixed Americans.[13](#cpt690-bib-0013){ref-type="ref"} Frequencies of variants outside of coding regions were extracted from 1,851 genomes provided by the 1000 Genomes Project.[12](#cpt690-bib-0012){ref-type="ref"} For alleles that were defined by a set of variants, as specified in **Tables** [1](#cpt690-tbl-0001){ref-type="table-wrap"}, [2](#cpt690-tbl-0002){ref-type="table-wrap"}, [3](#cpt690-tbl-0003){ref-type="table-wrap"}, [4](#cpt690-tbl-0004){ref-type="table-wrap"}, [5](#cpt690-tbl-0005){ref-type="table-wrap"} and **Supplementary Tables S1--S4**, we calculated linkage of the respective SNVs using the LDhap feature of the software package LDLink (<https://analysistools.nci.nih.gov/LDlink>)[50](#cpt690-bib-0050){ref-type="ref"} based on population‐specific linkage information provided by the 1000 Genome Project. Frequencies of gene deletions (*CYP2A6\*4* and *CYP2D6\*5*) or amplifications (*CYP2D6\*1xN* and *CYP2D6\*2xN*) were obtained from the literature, as indicated due to technical limitations regarding the reliable quantification of their frequencies from synthesized short‐read sequencing projects. Cumulative allele frequencies (F~cum,i,p~) for each gene *i* were calculated for each population *p* by summing up the individual haplotype frequencies of all major alleles included in **Tables** [1](#cpt690-tbl-0001){ref-type="table-wrap"}, [2](#cpt690-tbl-0002){ref-type="table-wrap"}, [3](#cpt690-tbl-0003){ref-type="table-wrap"}, [4](#cpt690-tbl-0004){ref-type="table-wrap"}, [5](#cpt690-tbl-0005){ref-type="table-wrap"}. Average \*1 allele frequencies were determined as: $$F_{*1,i} = 1 - \sum\limits_{p}F_{cum,i,p}$$

5.2. Allele nomenclature and definitions {#cpt690-sec-0006}
----------------------------------------

*CYP* star (\*) alleles were defined according to the Human CYP Allele Nomenclature Database (<http://www.cypalleles.ki.se>) and we refer to this source for references describing the functional characterization of the respective alleles. In this study, we pooled suballeles and only considered the variants that effectuate the functional effects of the allele, as indicated in **Tables** [1](#cpt690-tbl-0001){ref-type="table-wrap"}, [2](#cpt690-tbl-0002){ref-type="table-wrap"}, [3](#cpt690-tbl-0003){ref-type="table-wrap"}, [4](#cpt690-tbl-0004){ref-type="table-wrap"}, [5](#cpt690-tbl-0005){ref-type="table-wrap"} and **Supplementary Tables S1--S4**. Throughout this paper, we defined common alleles as having MAF \>1%, whereas variants or alleles with an allelic frequency \<1% were defined as rare.
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**Supplementary Table S1** Important variant and allele frequencies of the human *CYP1A1* gene. AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians. For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>.
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Click here for additional data file.
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**Supplementary Table S2** Important variant and allele frequencies of the human *CYP1A2* gene. AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians. For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>. ^\#^ Indicates alleles whose functionality assessment is based solely on *in vitro* data.

###### 

Click here for additional data file.
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**Supplementary Table S3** Important variant and allele frequencies of the human *CYP2E1* gene. AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians. For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>. ^\#^ Indicates alleles whose functionality assessment is based solely on *in vitro* data.
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Click here for additional data file.
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**Supplementary Table S4** Important variant and allele frequencies of the human *CYP4F2* gene. AFR, Africans; AMR, admixed Americans; CYP, cytochrome P450; EAS, East Asians; EUR, Europeans; SAS, South Asians. For references describing the functional characterization of the indicated alleles, see <http://www.cypalleles.ki.se>.
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Click here for additional data file.
